Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634177 | 0.83 | — | — | |
| SCHEMBL7373252 | 0.78 | TDP1 (0.35) | — | |
| SCHEMBL19127561 | 0.76 | TSHR (0.33) | TSHRNQO1 | |
| SCHEMBL4771993 | 0.73 | MPO (0.32) | — | |
| SCHEMBL4807473 | 0.72 | — | — | |
| SCHEMBL8788415 | 0.71 | PLAU (0.31) | — | |
| SCHEMBL4019693 | 0.70 | — | — | |
| SCHEMBL5318359 | 0.70 | — | — | |
| SCHEMBL2309452 | 0.68 | — | — | |
| SCHEMBL16915161 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465808-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-16 | — | — | US | disclosed |
| EP-1603864-A4 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060014817-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | US | disclosed |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-05 | — | — | US | disclosed |
| EP-1603864-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078144-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014817-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GIPR | TSHR 164/4885NQO1 4518/4885 |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | CCKAR, CCKBR, FFAR1 | TSHR 301/4885NQO1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.